Role of Aspirin in Cancer Prevention
- 1.4k Downloads
Since its first synthesis in 1897, several medicinal roles and mechanisms of action of aspirin have become apparent; the latest among these being its role in cancer prevention and treatment. A large body of evidence supports aspirin’s effect in reducing cancer incidence and cancer mortality, but duration of use needs to be at least 5 years. The beneficial effects are particularly large for colorectal, oesophageal and gastric cancers, with apparently smaller reductions for breast, prostate and lung cancer. The major harm is gastrointestinal bleeding, but serious sequelae are minimal at ages <70 years. It is very likely that use of prophylactic aspirin in the general population aged 50–70+ years will result in net overall benefit. Outstanding issues are: whether standard dose (~300 mg/day) can lead to greater net benefits than low dose (75–100 mg/day), the optimum duration of use, and appropriate ages for use in average-risk individuals.
KeywordsAspirin Prevention Cancer Cardiovascular disease Myocardial infarction Stroke Peptic ulcer Gastrointestinal bleeding Benefit-harm Helicobacter pylori
Compliance with Ethics Guidelines
Conflict of Interest
Mangesh A. Thorat declares no conflict of interest.
Jack Cuzick is a member of Bayer advisory board.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 14.•• Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012. This overview of a large number of RCTs confirmed the benefits of aspirin on cancer incidence and mortality, as reported in an earlier overview of selected RCTs with long-term follow-up. It also confirmed that it takes at least 3 years for the beneficial effects to become apparent. Google Scholar
- 15.•• Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50. This expanded overview of RCTs confirmed the benefits of aspirin on colorectal cancer incidence and mortality, as reported in an earlier overview.PubMedCrossRefGoogle Scholar
- 16.•• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012. This overview of a large number of RCTs demonstrated that aspirin use at the time of cancer diagnosis and / or after diagnosis results in reduction in the risk of cancer metastasis. Google Scholar
- 24.•• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41. This overview of RCTs with long-term follow-up demonstrated the effect of aspirin on overall cancer deaths. It showed that it takes at least 3 years for the beneficial effects to become apparent. It also demonstrated that benefits are largest with scheduled treatment duration of 7.5 years or more.Google Scholar
- 28.• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–606. This study showed a large magnitude of aspirin benefits in colorectal cancer patients with PIK3CA mutation in their tumours. The finding of this study, if replicated, could help in personalising aspirin use in adjuvant treatment of colorectal cancer.PubMedCrossRefGoogle Scholar
- 41.• Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7. This RCT in individuals at high risk of colorectal cancer showed a large benefit in aspirin users with just 2 years of scheduled treatment and in a relatively shorter follow-up time. High underlying risk and use of a larger aspirin dose (600 mg/day) could be the reasons for early benefit of large magnitude.PubMedCrossRefGoogle Scholar
- 42.•• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012. This overview of a large number of RCTs and observational studies confirmed the benefits of aspirin on cancer. It also showed that the effects seen in RCTs and case-control studies are largely consistent. Google Scholar
- 43.•• Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23. This overview of a large number of observational studies demonstrated the benefits of aspirin on cancer incidence and mortality for several cancer sites. Authors also investigated effects of dose and duration separately for each site.Google Scholar
- 44.•• Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85. These long-term results of a large RCT (WHS) have conclusively demonstrated aspirin’s effect in reducing colorectal cancer incidence. It took 10 years for the beneficial effects to become apparent, but a large magnitude (42 %) of post-treatment benefit and an overall 20 % reduction is consistent with rest of the literature. Of particular importance is the fact that such large benefit was seen even when only 100 mg aspirin was taken on alternate days.Google Scholar
- 47.• Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012;104:1208–17. These long-term results of a large cohort (CPS-II Nutrition cohort) have shown the beneficial effects of aspirin on reduction in cancer mortality.PubMedCrossRefGoogle Scholar
- 66.•• Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–9. This overview of RCTs investigated aspirin-related bleeding harms, GI bleeding, major bleeding and haemorrhagic strokes.PubMedCrossRefGoogle Scholar
- 85.CancerStats—Cancer Statistics for the UK. 2011. Available at http://info.cancerresearchuk.org/cancerstats/. Accessed 25/04/2011.
- 87.Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust. 2008;189:105–9.PubMedGoogle Scholar